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Abstract: Carotid artery stenting (CAS) is a minimal invasive procedure used to resolve carotid
occlusion that can be affected by peri-procedural complications. Statin use before CAS has shown to
reduce peri-procedural risk and improve survival, though time-dependent cofactors that influence
mortality has not been considered. The aim of this study was to evaluate long-term survival of
patients who undergo CAS considering new occurred major adverse cardiovascular event (MACE) as
time-dependent cofactor. In this study, 171 high cardiovascular risk patients (age 72 ± 8 years,
125 males) were enrolled after CAS procedure and were followed for a median of 8.4 years.
Death occurred in 44% of patients with a mean time to death of 69 ± 39 months and MACE
in 34% with a mean time of 35 ± 42 months. In patients who used or not statins at baseline,
death occurred in 33% and 65%, respectively (p < 0.001). Survival analysis showed that statin
use reduced risk of death (hazard ratio HR 0.36, 95% confidence interval CI 0.23–0.58, p < 0.0001).
Including MACE as time-dependent variable did not change beneficial effects of statins. Additionally,
statin use was associated with a protective effect on MACE (HR 0.48, 95% CI 0.27–0.85, p = 0.012);
particularly, the prevalence of stroke was reduced by 59% (p = 0.018). In multivariate analysis,
effects of statins were independent of demographic and anthropometric variables, prevalence of
cardiovascular risk factors, renal function, antiplatelet use, and MACE occurrence. In conclusion,
use of statins before CAS procedure is associated with increased long-term survival and reduced
MACE occurrence. This evidence supports the hypothesis that statin use before CAS might be
beneficial in high risk patients.
Keywords: statins; atherosclerosis; carotid artery stenting; mortality; cardiovascular event
1. Introduction
Statins are effective in cardiovascular primary and secondary prevention by reducing the incidence
of cardiovascular events and mortality [1]. Statins reduce total and LDL-cholesterol levels that
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are implicated in the development and progression of atherosclerotic arterial lesions with an effect
that is wider than effects related just to LDL-cholesterol reduction [2]. Although evidence of the
protective effects of statins in cardiac and extra-cardiac revascularization is recognized [3,4], benefit of
statins use in the prevention of major adverse cardiovascular events (MACE) and long-term mortality
after CAS has been suggested in a single observational study [5]. In this multicenter Italian study,
more than 1000 patients were recruited after primary CAS, and statins were taken by 43% of patients
before the procedure. After a follow-up of 5 years, patients who took statins before CAS had lower
mortality and incidence of perioperative stroke than patients who did not take statins. The better
survival was imputed mainly to a lower incidence of perioperative stroke and late-occurred ischemic
stroke [5]. However, this latter evidence was only borderline significant, and the study did not consider
time-dependent events that could have influenced mortality, thus misestimating the potential beneficial
effect of statins on different outcomes. Similar results on post-operative mortality were shown in the
recent large retrospective analysis of Rizwan et al. on data of the Premier Healthcare Database, a large
American database that includes data of more than 700 U.S. hospitals [6].
Carotid artery disease as represented by atherosclerotic plaques is a common subclinical
organ damage seen in patients with cardiovascular risk factors such as diabetes, hypertension,
dyslipidemia, and smoking history and its prevalence increases progressively according to age.
Atherosclerotic plaque progression in internal carotid artery over a significant percentage of lumen
stenosis is associated with high risk of cerebrovascular events such as transient ischemic attack (TIA),
ischemic stroke, and retinal artery occlusion which can permanently impair patient’s autonomy and
life-expectancy. Carotid artery stenting (CAS) is an effective procedure for patients with critical or
symptomatic internal carotid artery stenosis for preventing cerebrovascular events and mortality [7].
This procedure might be preferred in high risk patients because it is less invasive and associated with
lower peri-procedural cardiac events than surgical endarterectomy [8]. However, CAS is affected by
an increased risk of post-procedural stroke respect to endarterectomy and the best choice between the
two procedures is left just to local experience [9].
Recently, prospective cohort studies showed that pre-procedural use of statins can reduce the
risk of peri-procedural CAS complications including stroke and mortality, but so far data on very
long-term survival considering time-dependent covariates that can influence survival beyond baseline
conditions have not been reported [10–12]. In the study of Gröschel et al. conducted in Germany,
180 patients were followed prospectively 30 days after CAS for high-grade symptomatic carotid
stenosis. Patients who took statins before procedure (29% of all patients) had a lower incidence of the
composite endpoint (stroke, myocardial infarction, and death) than patients who did not take statins;
4% and 15%, respectively [10]. Similar results were shown more recently by Reiff et al. in 344 other
patients, 60% of whom took statins before CAS [11]. Also, Hong et al. demonstrated on 397 Korean
patients that the protective post-procedural benefit of statins used before CAS on cardiovascular
events and death was clearly dose-dependent [12]. Very recently, a meta-analysis on randomized
trial and observational studies confirmed a beneficial effect of the pre-procedural statins’ intake on
peri-procedural risk of stroke and death [13].
Considering promising results and limitations of previous studies, our aim was to assess very
long-term survival (beyond 5 years of follow-up) of patients who undergo CAS procedure and who
were taking or not taking statins at baseline in a retrospective analysis that considers the occurrence of
new MACE during follow-up as time-dependent covariate.
2. Patients and Methods
In this retrospective study we included consecutively patients that underwent primary CAS
procedure for a significant carotid artery stenosis after multidisciplinary evaluation by an internist,
a neurologist, and an interventional radiologist. When appropriate a vascular surgeon was involved to
confirm clinical indication to CAS procedure. All patients underwent CAS between 2003 and 2008 and
were followed at our Cardiovascular Risk and Atherosclerotic Prevention Center until the end of 2016.
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Patients were considered for CAS procedure when they were at elevated surgical risk for age or for
the presence of severe comorbidities, refused endarterectomy instead of CAS, had a favorable carotid
anatomy. Carotid revascularization was offered to patients with a stenosis of the internal carotid artery
confirmed by computer tomography or magnetic resonance angiography greater than 60% of the
internal lumen or if they were asymptomatic but presented a confirmed stenosis of more than 70% and
showing cerebral imaging of ipsilateral silent infarctions. Symptomatic patients were considered those
with history of TIA, stroke or retinal artery occlusion occurred in the six months before evaluation and
whose cerebral ischemic lesions were confirmed by radiological imaging that is concordant with the
lesion’s side.
All patients were evaluated by the internist for the presence of major cardiovascular risk factors
according to current guidelines [14]. Blood pressure, anthropometric and other general clinical
variables were collected, and biochemical laboratory measurements had been performed for assessing
lipid and glucose metabolism and renal function. Diagnosis of hypertension was defined by current use
of antihypertensive drugs or by at least two in-office independent repeated measurements of systolic
and/or diastolic blood pressure levels greater than 139 and 89 mmHg, respectively. Diabetes was
defined by use of oral antidiabetic drugs or insulin or by at least two independent morning fasting
glucose measurements greater than 125 mg/dL and/or a glycated hemoglobin greater than 6.4%.
Dyslipidemia was defined by use of lipid-lowering drugs or at least two independent morning plasma
fasting total cholesterol measurements greater than 200 mg/dL. Body mass index was defined as
weight in Kg over squared height in meters and glomerular filtration rate has been estimated (eGFR) by
the equation of Cockcroft-Gault. Baseline prevalence of cardiovascular diseases such as chronic angina,
ischemic cardiomyopathy, cerebrovascular diseases, atrial fibrillation, and peripheral artery diseases
was assessed by clinical interviews, medical visits, and patients’ medical records. Dual antiplatelet
therapy with aspirin (ASA) 100 mg/day and either clopidogrel 75 mg/day or ticlopidine 500 mg/day
was started at least 3 days before CAS procedure in all patients.
All patients were evaluated by a neurologist for assessment of TIA or stroke signs and by
an ophthalmologist in case of retinal artery occlusion. A neurologist or radiologist performed the carotid
duplex ultrasound in high risk patients that came into the attention of our Center or the neurological
division. Carotid artery stenosis was quantified by the criteria of the North American Symptomatic
Carotid Endarterectomy Trial (NASCET). Finally, an interventional radiologist checked clinical indications,
evaluated technical aspects from radiological imaging, and confirmed CAS procedure [15].
CAS procedure was performed with the assistance of an anesthetist that induced a mild sedation
of patients and monitored they vital signs during the procedure providing advance life support when
necessary. After local anesthesia, the interventional radiologist performed stenting via the femoral
artery or via brachial or radial arteries when the femoral access was problematic. A temporarily filter
device was introduced with catheter to reduce the risk of cerebral embolization during angioplasty and
stenting. Intravenous heparin (100 U/Kg) was infused during the procedure. Immediately after CAS
procedure patients were taken to the ward of the Department of Medicine to monitor vital parameters
and possible signs of acute cerebrovascular complications. Generally, patients were discharged from
the hospital on the third day after CAS procedure. Carotid duplex ultrasound was repeated at 1 and
6 months after CAS procedure then at 1 and 2 years from procedure to assess carotid restenosis.
Dual antiplatelet therapy was continued for at least 3 months after CAS, then a single antiplatelet drug
was routinely taken for chronic use (mainly ASA if tolerated). Patients were revaluated by the internist
at 3 and 6 months and then annually to monitor cardiovascular risk factors, adherence to treatments,
and register new MACE occurrence. Patients not compliant to regular controls were contacted by
telephone and electronic records were consulted when available to check the clinical status or death.
MACE that occurred within 1 month from CAS procedure were considered as peri-procedural event.
Giving the retrospective design of this study, causes of death where not available for most patients.
For definition of MACE, we considered one of the following events: TIA, ischemic or hemorrhagic
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stroke, myocardial infarction, acute coronary artery disease, or arterial revascularization procedures
other than CAS.
This study was approved by the Institutional Review Board of the University of Udine
(40/IRB_COLUSSI_18) and the written consent of participants was collected according to the Italian
law on retrospective studies.
Statistical Analysis
Data are presented as mean ± standard deviation for normal-distributed variables and as median
(interquartile range) for skewed ones. Normal distribution of variables was assessed by histogram view
and the Shapiro-Wilk normality test. Skew variables were log-transformed before use in parametric
analysis. Comparisons between means were performed with the Student-t-test, whereas comparisons
between proportions with chi-square or exact Fischer tests as needed. Multivariate analysis of
dichotomous dependent variables was performed with the logistic regression and coefficients were
reported as adjusted Odds Ratio (OR) with the 95% confidence interval (CI).
For the survival analysis we consider both a classic Cox model with time to MACE as a covariate
and a multi-state transition (illness-death) model with the occurrence of new MACE during follow-up
as the only time-dependent covariate (Figure 1) [16]. Survival analysis of patients stratified in statin
users and non-users was represented by Kaplan-Meier curves and analyzed by the not-parametric
log-rank test. Influence of covariates including statins use on survival rate was assessed by Cox
proportional hazards analysis considering a Markov model for the multi-state transition with
a clock-forward approach [17]. Transition hazards in MACE or death from baseline status were
considered to be proportional (Figure 2). In all models, anthropometric variables, major cardiovascular
risk factors, renal function as expressed by estimated glomerular filtration rate with the Cockcroft-Gault
formula, use of statin and antiplatelet drugs before CAS procedure, and months to first MACE
occurrence were included as covariates. Coefficients were reported as Hazard Ratio (HR) and 95% CI.
Because all patients with dyslipidemia took statins we did not include dyslipidemia as covariate for
collinearity problems.
For the multi-state Markov model analysis, age, BMI, and renal function were categorized
to make clear the interpretation of HR. Age was divided into three classes according to age at
enrollment lower than 65 years, between 65–75 years, and greater than 75 years BMI was divided
into three classes according to BMI lower than 25 Kg/m2, between 25–30 Kg/m2, and greater than
30 Kg/m2. Renal function was classified into three classes that included renal failure of stage I,
stage II, and stage III + IV, respectively. Stages were defined as established by the Kidney Disease:
Improving Global Outcomes (KDIGO) criteria on estimated glomerular filtration rate [18]. For statistical
reasons, when deaths and MACE overlapped, we arbitrary considered that MACE occurred one week
before death.
Data collection was complete without missing values and the null-hypothesis was rejected when
tests’ two-tails probabilities were equal or less than 5%. For statistical analysis and graphs we used R
software (Version 3.4.3) with survival (Version 2.41–3), mstate (Version 0.2.10), survminer (Version 0.4.2),
and diagram (Version 1.6.4) packages [17,19].
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3. Results
In this study, 171 patients, age 72 ± 8 years, who underwent CAS procedure were enrolled
and followed for a median of 101 months (range 2–173). Death occurred in 44% of patients after
a mean follow-up of 69 ± 39 months and a new MACE occurred in 34% after 35 ± 42 months
(Table 1). Baseline prevalence of major cardiovascular risk factors in the sample was: male sex 73%,
smoking history 67%, hypertension 85%, diabetes 46%, dyslipidemia 71%, and pre-existent MACE
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68%. Prevalence of cardiovascular diseases at baseline included: atrial fibrillation 9%, ischemic heart
disease 36%, and peripheral artery diseases other than carotid stenosis 33%. Moderate renal failure
(eGFR less than 60 mL/min/1.73 m2) was observed in 36% of patients. Statins were used by 66% of
patients before CAS, and molecules consisted of simvastatin in 41%, atorvastatin in 40%, rosuvastatin
in 15%, and pravastatin in 4% of statin users. The range of statin dose taken by patients was 20–40 mg
for simvastatin, 20–80 mg for atorvastatin, 10–40 mg for rosuvastatin, and 20–40 mg for pravastatin.
Patients who died within the study period were older at enrollment (+4 years) and had greater
prevalence of diabetes (+79%) and atrial fibrillation (3-fold), but lower use of statins (–38%) and
a shorter time of follow-up (–32 months) and time to first MACE occurrence (–23 months) than
alive/censured patients (Table 1). In patients who developed new MACE, death occurred in
41% after 85 ± 45 months, whereas in patients without new MACE, death occurred in 45% after
86 ± 45 months. Characteristics of patients with MACE did not differ from those of patients who
did not have MACE during follow-up (Table 1). Patients that use statins at baseline were 5 years
younger at enrollment and had greater eGFR (+13%), more prevalent dyslipidemia and ischemic
heart disease, and longer time to death (+9 months), time to new MACE (+26 months), and average
follow-up time (+19 months) than patients that did not use statins. Death among statin users was
49% lower than among non-users (Table 1). Peri-procedural complications after CAS occurred
in 14 (8.2%) patients, of which 6 (3.5%) with and 8 (4.7%) without baseline statin use (p = 0.076).
In the multivariate logistic-regression model including sex, age, smoking history, baseline BMI, eGFR,
use of antiplatelet drugs, prevalence of diabetes, hypertension, and pre-existent MACE, statin use
was negatively associated with peri-procedural complications (adjusted OR 0.16, 95% CI 0.04–0.58,
p = 0.007). Peri-procedural complications consisted only of TIA/minor stroke. Neither peri-procedural
deaths nor other cardiovascular events were reported.
Kaplan-Meier curves of patients stratified in statin users and non-users are presented in Figure 3.
Patients who used statins pre-procedurally had a better survival rate than patients who did not
(unadjusted HR 0.36, 95% CI 0.23–0.58, p < 0.0001). In the classic Cox model, the effect of statins on
mortality (adjusted HR 0.56, 95% CI 0.33–0.94, p = 0.028) was independent of sex, smoking history,
baseline BMI, estimated creatinine clearance, use of antiplatelet drugs and prevalence of hypertension,
diabetes and preexistent MACE, and time of occurrence of new MACE. Other variables independently
associated with mortality were age at enrollment (adjusted HR 1.08, 95% CI 1.04–1.13, p < 0.001),
baseline prevalence of diabetes (adjusted HR 2.45, 95% CI 1.49–4.04, p < 0.001), and months to
occurrence of a new MACE (HR 0.987, 95% CI 0.981–0.992, Table 2).
Analysis of the Markov multi-state model is shown in Table 3. Proportion of patients and mean
± standard deviation values in different class of age, BMI, and stage of renal failure are showed in
Table 4. All HR were adjusted for all covariates. The only factor that affected the transition from CAS
procedure to MACE (transition 1 in Figure 1) was statin use (HR 0.48, 95% CI 0.27–0.85, p = 0.012).
Factors that affected transition from CAS to death (transition 2 in Figure 1) were age at enrollment
greater than 75 years (HR 4.47, 95% CI 1.23–16.10, ref. age < 65 years, p = 0.023), prevalence of diabetes
(HR 2.29, 95% CI 1.23–4.27), and statin use (HR 0.43, 95% CI 0.22–0.84). Factors that affected transition
from MACE to death (transition 3 in Figure 1) were age at enrollment equal or greater than 65 years
(age 65–75 years HR 0.04, 95% CI 0.004–0.345, p = 0.004 and age > 75 years HR 0.12, 95% CI 0.02–0.84,
p = 0.033, ref. age < 65 years), renal failure greater than stage II (HR 46.5, 95% CI 2.09–1034.0, p = 0.015,
ref. stage I), prevalence of diabetes (HR 5.00, 95% CI 1.26–20.0, p = 0.022), and statin use (HR 0.12,
95% CI 0.03–0.47, p = 0.002). Analysis of new MACE or death prevalence during follow-up did not
change according to different statin types.
In Table 5, types of principal cardiovascular events that occurred during the follow-up were
analyzed in patients who used or not statins before CAS. The only difference was seen in the prevalence
of fatal and non-fatal stroke (59% lower in patients who used statins, p = 0.018). No differences were
seen for the prevalence of transitory ischemic attack or fatal and non-fatal ischemic heart disease.
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Table 1. General characteristic of all studied patients and of patients divided by groups: censored or
death, with or without new MACE occurrence, and using or not using statins at baseline.
Variable All(n = 171)
Censored
(n = 96)
Died
(n = 75)
−MACE
(n = 112)
+MACE
(n = 59)
−Statins
(n = 58)
+Statins
(n = 113)
Enrolment age (years) 72 ± 8 70 ± 8 74 ± 9 *** 72 ± 9 72 ± 8 75 ± 8 70 ± 8 ***
Male sex (n (%)) 125 (73) 70 (73) 55 (73) 86 (77) 39 (66) 43 (77) 82 (71)
Smoke history (n (%)) 115 (67) 62 (64) 53 (71) 76 (68) 39 (66) 44 (76) 71 (63)
BMI (Kg/m2) 26.4 ± 3.8 26.3 ± 3.6 26.5 ± 4.1 26.2 ± 3.7 26.7 ± 4.0 25.8 ± 4.0 26.7 ± 3.7
SBP (mmHg) 159 ± 25 159 ± 23 159 ± 28 158 ± 24 161 ± 27 160 ± 28 158 ± 24
DBP (mmHg) 84 ± 13 82 ± 10 86 ± 17 84 ± 14 84 ± 12 85 ± 18 83 ± 11
eGFR (mL/min/1.73 m2) 67 ± 23 70 ± 21 64 ± 25 67 ± 23 67 ± 23 62 ± 22 70 ± 23 *
Hypertension (n (%)) 146 (85) 77 (80) 69 (92) 96 (86) 50 (85) 46 (79) 100 (88)
Diabetes (n (%)) 79 (46) 33 (34) 46 (61) *** 53 (47) 26 (44) 25 (43) 54 (48)
Dyslipidemia (n (%)) 121 (71) 73 (76) 48 (64) 80 (71) 41 (69) 13 (22) 108 (96) ***
Atrial fibrillation (n (%)) 16 (9) 4 (4) 12 (16) * 11 (10) 5 (8) 6 (10) 10 (9)
IHD (n (%)) 61 (36) 34 (35) 27 (36) 37 (33) 24 (41) 12 (21) 49 (43) ***
Peripheral artery disease (n (%)) 57 (33) 29 (30) 28 (37) 38 (34) 19 (32) 17 (29) 40 (35)
Carotid restenosis (n (%)) 12 (7) 6 (6) 6 (8) 6 (5) 6 (10) 4 (7) 8 (7)
Preexistent MACE (n (%)) 116 (68) 65 (68) 51 (68) 75 (67) 41 (69) 34 (59) 82 (73)
Statins users (n (%)) 113 (66) 76 (79) 37 (49) *** 79 (70) 34 (58) 0 (0) 115 (100)
Antiplatelet users (n (%)) 156 (91) 89 (93) 67 (89) 103 (92) 53 (90) 54 (93) 102 (90)
Follow-up (months) 87 ± 45 101 ± 44 69 ± 39 *** 86 ± 45 87 ± 45 74 ± 45 93 ± 43 **
New MACE (n (%)) 59 (34) 35 (36) 24 (32) 0 (0) 59 (100) 25 (43) 34 (30)
Time to new MACE (months) 68 ± 50 78 ± 54 55 ± 42 ** 86 ± 45 35 ± 42 *** 51 ± 47 77 ± 50 **
MACE within 1 month (n (%)) 14 (8.2) 5 (5) 9 (12) - 14 (100) 8 (14) 6 (5)
Deaths (n (%)) 75 (44) 0 (0) 75 (100) 51 (45) 24 (41) 38 (65) 37 (33) ***
Time to death (months) 69 ± 39 - 69 ± 39 86 ± 45 89 ± 45 74 ± 45 93 ± 43 **
MACE, major adverse cardiovascular events; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; −, without; +, with;
* p < 0.050, ** p < 0.010, *** p < 0.001.
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Table 2. Classic Cox proportional hazard regression analysis.
Variable HR 95% CI p
Enrolment age (years) 1.08 (1.04–1.13) <0.001
Male sex (no/yes) 1.34 (0.70–2.55) NS
Smoke history (no/yes) 0.77 (0.41–1.46) NS
BMI (Kg/m2) 0.99 (0.91–1.09) NS
eGFR (mL/min/1.73 m2) 1.00 (0.99–1.02) NS
Hypertension (no/yes) 2.00 (0.83–4.81) NS
Diabetes (no/yes) 2.45 (1.49–4.04) <0.001
Preexistent MACE (no/yes) 0.96 (0.54–1.71) NS
Statins users (no/yes) 0.56 (0.33–0.94) 0.028
Antiplatelet users (no/yes) 1.20 (0.57–2.55) NS
Time to new MACE (months) 0.987 (0.981–0.992) <0.001
BMI, body mass index; MACE, major adverse cardiovascular events; HR, hazard ratio; CI, confidence interval; NS,
not significant; p, probability.
Table 3. Clock-forward multi-state Markov model analysis.
Variable
Transition 1
CAS to MACE
(n = 59)
Transition 2
CAS to DEATH
(n = 51)
Transition 3
MACE to DEATH
(n = 24)
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Enrolment age (years) <65 Ref. Ref. Ref.
65–75 1.43 (0.64–3.20) NS 2.23 (0.68–7.27) NS 0.04(0.004–0.345) 0.004
>75 1.42 (0.55–3.68) NS 4.47 (1.23–16.10) 0.023 0.12 (0.02–0.84) 0.033
Sex Female Ref. Ref. Ref.
Male 0.52 (0.24–1.12) NS 1.83 (0.70–4.77) NS 1.78 (0.47–6.89) NS
Smoke history No Ref. Ref. Ref.
Yes 1.12 (0.55–2.28) NS 0.62 (0.28–1.36) NS 0.40 (0.10–1.70) NS
BMI class (Kg/m2) <25 Ref Ref. Ref.
25–30 1.50 (0.81–2.81) NS 1.68 (0.83–3.43) NS 1.86 (0.55–6.32) NS
>30 1.08 (0.39–2.97) NS 2.86 (0.97–8.37) NS 3.50 (0.27–46.0) NS
Stage of renal failure Stage I Ref. Ref. Ref.
Stage II 0.84 (0.37–1.90) NS 0.54 (0.19–1.55) NS 11.0 (0.74–162) NS
Stage III +
IV 0.77 (0.28–2.09) NS 2.13 (0.66–6.90) NS 46.5 (2.09–1034) 0.015
Hypertension No Ref. Ref. Ref.
Yes 0.94 (0.43–2.06) NS 1.60 (0.55–4.64) NS 6.35 (0.43–93.9) NS
Diabetes No Ref. Ref. Ref.
Yes 1.13 (0.66–1.94) NS 2.29 (1.23–4.27) 0.009 5.00 (1.26–20.0) 0.022
Preexistent MACE No Ref. Ref. Ref.
Yes 1.64 (0.88–3.03) NS 1.93 (0.96–3.89) NS 0.31 (0.07–1.47) NS
Statin users No Ref. Ref. Ref.
Yes 0.48 (0.27–0.85) 0.012 0.43 (0.22–0.84) 0.014 0.12 (0.03–0.47) 0.002
Antiplatelet users No Ref. Ref. Ref.
Yes 0.84 (0.35–1.98) NS 1.37 (0.50–3.70) NS 1.84 (0.42–8.14) NS
New MACE occurrence 2.79 (0.01–556.4) NS
Time to new MACE (months) 1.01 (0.98–1.03) NS
CAS, carotid artery stenting; MACE, major adverse cardiovascular events; BMI, body mass index; Ref.,
reference group; HR, hazard ratio; CI, confidence interval; NS, not significant; p, probability.
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Table 4. Description of class variables.
Age Class (Years) <65 65–75 >75 p
n (%) 32 (19) 73 (43) 66 (38)
<0.001Age 59 ± 2 70 ± 3 80 ± 4
BMI Class (Kg/m2) <25 25–30 >30 p
n (%) 71 (42) 76 (44) 24 (14)
<0.001BMI 23.3 ± 1.5 27.2 ± 1.4 32.9 ± 4.1
Renal Failure Stage I II III + IV p
n (%) 27 (16) 80 (47) 74 (37)
<0.001eGFR (mL/min/1.73 m2) 124 ± 22 78 ± 11 47 ± 10
BMI, body mass index; p, probability.
Table 5. Prevalence of newly occurred major cardiovascular events during follow-up in patients who
used or did not use statins before carotid artery stenting.
Event All Patients(n = 171)
−Statins
(n = 58)
+Statins
(n = 113) p
Transitory ischemic attack (n (%)) 26 (15) 9 (15) 17 (15) NS
Fatal and non-fatal stroke (n (%)) 23 (13) 13 (22) 10 (9) 0.018
Fatal and non-fatal ischemic heart
disease (n (%)) 35 (20) 10 (17) 25 (22) NS
p, probability; NS, not statistically significant by Fisher exact test; −, without; +, with.
4. Discussion
In this retrospective study, we showed that pre-procedural statin use is associated with improved
long-term survival in patients who undergo carotid artery angioplasty and stenting. Additionally,
statin use was associated with a lower risk of new MACE occurrence after CAS procedure in
a multi-state (illness-death) model analysis. These effects of statins were independent of cofactors.
The protective effect of statins on the onset of peri-procedural complications and long-term
cardiovascular events and mortality after angioplasty and stenting has been demonstrated in coronary
and other arterial sites [4,20], as well as in carotid surgical endarterectomy [21]. Previous studies have
extended this evidence also in carotid artery stenosis regarding peri-procedural complications [6,11,13]
and 5-years mortality [5]. Our study confirms previous observations showing a beneficial effect of
statins on survival rate and extends this observation over 8 years after CAS procedure also providing
additional evidence of beneficial effect of these drugs on new MACE occurrence and, particularly,
on the new onset of fatal and non-fatal stroke. Most importantly, our results come from a more accurate
multi-state Markov model that takes into account contemporary time-dependent events (new MACE
occurrence) that influence mortality rate and that cannot be considered in a classic Cox regression
model of survival analysis [16].
Although in our study statins effect on mortality was independent of MACE occurrence during
follow-up, time to MACE was inversely associated with mortality in the classic Cox model, so that
the earlier was MACE occurrence the higher was mortality rate (about 1% per month, Table 3).
Additionally, in the Markov model patients younger than 65 years with MACE had a greater risk
of death than older patients, although in the classic Cox model age was associated with mortality
independently of MACE. This observation shows the higher accuracy of the multi-state model than
the classic Cox model to analyze time-to-event studies and suggests that MACE occurrence in younger
patients after CAS can be greater than in the older ones.
Angioplasty and stenting are procedures that activates vascular wall inflammation,
platelet activation, and induce a local prothrombotic state that is responsible for vessel restenosis
J. Clin. Med. 2018, 7, 286 10 of 12
or thrombo-embolic events [22]. Also, in the case of CAS elderly patients are at increased risk of
peri-procedural complications such as embolic stroke and/or death than patients treated with surgical
endarterectomy [23,24]. Nevertheless, CAS is a less invasive intervention than surgical endarterectomy
and more appealing for patients at elevated surgical risk such as the elderly and/or patients with
important comorbidities. This study suggests that an optimization of drug therapy before CAS might
improve procedure effectiveness [25]. In this regard, a randomized controlled trial with high dose
rosuvastatin on peri-procedural complications in dyslipidemic patients who undergo CAS procedure
is ongoing and will provide important information in the next years [26].
Statins inhibit 3-hydroxy-3-methylglutaryl-CoA-reducatse enzyme that is involved in endogenous
cholesterol synthesis in the liver and, by that, main statin effect is to reduce circulatory total and
LDL cholesterol levels. The lipid-lowering effect of statins is considered fundamental to stabilize
atherosclerotic plaque in which LDL cholesterol exerts an important etiopathogenic role, so that statins
reduce cardiovascular risk and mortality [2]. However, Hong et al. had demonstrated a dose-dependent
protective effect of statins on CAS peri-procedural complications that is independent of baseline
lipid profile suggesting a possible pleiotropic effect of these drugs beyond their lipid effect [12].
Accordingly, a prothrombotic and/or proinflammatory state is associated with subclinical arterial
damage in cardiovascular risk patients [27,28] and statins have clearly shown antithrombotic and
antinflammatory properties that might contribute to their role in preventing cardiovascular disease
and mortality [29]. We hypothesize that such a pleiotropic effect of statins might be involved in early
and late protective effects of these drugs on cardiovascular event and mortality after CAS by stabilizing
the atherosclerotic plaque. Accordingly, Tadros et al. demonstrated that in patients who undergo CAS,
pre-procedural statin use is associated with less embolic debris captured by the carotid filter during
the procedure, thus, providing evidence of a greater plaque stability in statin users [30].
This study has several limitations that should be highlighted. First, the retrospective design of
the study does not permit to give a causal relevance to our findings. We just hypothesize potential
associations that should be confirmed in prospective studies or randomized controlled trials. Second,
causes of death cannot be established for most of patients so that an analysis of statin effect on specific
events was not possible. Third, the dose of statins and baseline lipid levels, as well as new treatments
and plasma lipid changes during follow-up were not available for most patients. Patients could have
stopped or started new therapies during follow-up that could have influenced the mortality rate.
Also, we were not able to estimate statin withdrawal associated with their adverse effects during
the follow-up. Forth, this is a single center study with the experience of a hospital that serves the
population of the North-East of Italy. In our center, as in others, CAS procedure is not the preferred
procedure for significant carotid stenosis compared to surgical endarterectomy that results in the
most prevalent choice. Therefore, our small sample number could have limited the evidence of the
expected beneficial effect of statins on peri-procedural complications, although in the multivariate
logistic analysis such an evidence was demonstrated (adjusted 6 times lower odds of developing
peri-procedural complications with statin use, p = 0.007).
5. Conclusions
In this retrospective study we have demonstrated that baseline use of statin in patients that
undergo CAS is associated with better long-term survival and lower rate of MACE occurrence than in
patients not using statins. Among MACE, fatal and non-fatal stroke was the only event with a lower
prevalence in statins-user patients at the end of the follow-up. Although this study does not provide
a causal evidence, it provides the rationale for designing long-term prospective studies or randomized
controlled trials to optimize drug therapy of patients who undergo CAS.
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